Filtered By:
Drug: Victoza
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 100 results found since Jan 2013.
Treatment of Diabetes in Patients with Heart Failure
AbstractPurpose of ReviewThis review aims to summarize and discuss heart failure outcomes for current glucose-lowering agents in patients with type 2 diabetes mellitus.Recent FindingsCurrent regulations require cardiovascular outcomes trials for new glucose-lowering therapies to establish that there is no unacceptable increase in cardiovascular risk prior to approval. These cardiovascular outcomes trials include glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Overall, 87,162 patients have been studied in 10 published cardiovascular outcomes trials...
Source: Current Cardiology Reports - August 27, 2018 Category: Cardiology Source Type: research
Liraglutide Protects Neurite Outgrowth of Cortical Neurons Under Oxidative Stress though Activating the Wnt Pathway
Neurogenesis including neurite outgrowth is important for brain plasticity under physiological conditions and in brain repair after injury. Liraglutide has been found to have neuroprotective action in the risk of central nervous system disease. However, the effect and the potential mechanism of liraglutide-induced neurite outgrowth in primary cortical neurons under oxidative stress remain poorly documented.
Source: Journal of Stroke and Cerebrovascular Diseases - July 3, 2018 Category: Neurology Authors: Weiliang He, Xiaochao Tian, Mimi Lv, Hebo Wang Source Type: research
New antihyperglycaemic agents and cardiovascular disease: let's be optimistic
Purpose of review
Cardiovascular disease (CVD) substantially increases mortality in diabetes mellitus. This narrative review highlights recent research on the putative associations between dipeptyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter 2 inhibitors (SGLT-2is) and several cardiovascular risk factors.
Recent findings
New antihyperglycaemic agents favourably modulate several CVD risk factors, including fasting and postprandial plasma glucose levels, body weight, blood pressure, lipids, microalbuminuria, nonalcoholic fatty liver disease, serum uric a...
Source: Current Opinion in Cardiology - June 11, 2018 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research
Leptin, cardiovascular diseases and type 2 diabetes mellitus.
Abstract
Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - June 7, 2018 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Banach M Tags: Acta Pharmacol Sin Source Type: research
Liraglutide Attenuates the Depressive- and Anxiety-like Behaviour in the Corticosterone Induced Depression Model Via Improving Hippocampal Neural Plasticity.
Abstract
Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk factor of psychiatric diseases. This relationship opens the opportunity to develop new antidepressant drugs by repurposing antidiabetic drugs. Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. In addition, the GLP-1 analog liraglutide has been shown to promote neurogenesis, which is seen to play important roles in memory formation and cognitive and emotional processing. However...
Source: Brain Research - April 26, 2018 Category: Neurology Authors: Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W Tags: Brain Res Source Type: research
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide vs 339 wit h placebo).
Source: The American Journal of Cardiology - March 15, 2018 Category: Cardiology Authors: Steven P. Marso, Michael A. Nauck, Tea Monk Fries, S øren Rasmussen, Marianne Bach Treppendahl, John B. Buse, LEADER Publication Committee on behalf of the LEADER Trial Investigators Source Type: research
Myocardial Infarction Subtypes in Patients with Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (From the LEADER Trial)
Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the LEADER trial (N=9340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, non-fatal MI or non-fatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk of first MI (292 events with liraglutide versus 339 with placebo). This post hoc analysis characterized MIs (first and recurrent) occurring in LEADER, by treatment arm and regarding incidence, outcome, subtype and troponin levels.
Source: The American Journal of Cardiology - March 15, 2018 Category: Cardiology Authors: Steven P. Marso, Michael A. Nauck, Tea Monk Fries, S øren Rasmussen, Marianne Bach Treppendahl, John B. Buse, LEADER Trial Investigators Source Type: research
Integrating cardioprotective glucose-lowering medications into clinical practice
Patients with type 2 diabetes suffer from both microvascular and macrovascular complications. Optimal glycemic control is well known to reduce the microvascular complications of retinopathy, nephropathy, and neuropathy. However, despite having multiple classes of antidiabetes medications, we have not been able to favorably affect the cardiovascular (CV) complications of diabetes, which cause considerable morbidity and premature CV mortality in patients with diabetes. The recent publication of the EMPA-REG Outcome and the LEADER studies demonstrating favorable CV outcomes with empagliflozin and liraglutide have led to a dec...
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Practice Pearl: Liraglutide and Cardiovascular and Renal Events in Type 2 Diabetes.
Authors: Guthrie R
Abstract
Review of: Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322. Mann J, Orsted D, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 839-848. This comprehensive research project, LEADER, led to two reports, one focusing on the effect of liraglutide on cardiovascular events, and the second one reporting on the renal effects on the same study population. The study group included 9340 patients with type 2 diabetes. Patients were required to have type 2 diabet...
Source: Postgraduate Medicine - January 21, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Delayed Administration of the Glucagon-Like Peptide 1 Analog Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice
Glucagon-like peptide 1 (GLP-1) analogs administered before or after cerebral ischemia have been shown to provide neuroprotection. Here, we explored whether delayed administration of a GLP-1 analog, liraglutide, could improve long-term functional recovery and promote angiogenesis after stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 21, 2018 Category: Neurology Authors: Yanxia Chen, Xiangjian Zhang, Junna He, Yanzhao Xie, Yang Yang Source Type: research
The kidney and cardiovascular outcome trials
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) in nearly one in five patients, with increasing age, blood pressure, obesity, and levels of glycemia all associated with higher likelihood of Stage 3 or worse CKD, comparable to findings from surveys from many other areas, which also show micro‐ or macroalbuminuria to be present in one‐sixth to one‐third of diab...
Source: Journal of Diabetes - January 19, 2018 Category: Endocrinology Authors: Zachary Bloomgarden Tags: Editorial Source Type: research
Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Heart failure and diabetes commonly coexist, and therefore, drugs that favorably influence the natural history of each of these two disorders are likely to be prescribed together.1 In patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of major adverse cardiovascular events,2,3 and liraglutide is approved to reduce cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.4 Analogously, in patients with chronic heart failure and a reduced ejection fraction, neprilysin inhibition has been shown to decrease the risk of cardiovascular death and hospitalization for ...
Source: Journal of Cardiac Failure - January 3, 2018 Category: Cardiology Authors: Milton Packer Tags: Editorial Source Type: research
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials
The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time‐to‐event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0 mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person‐...
Source: Diabetes, Obesity and Metabolism - September 26, 2017 Category: Endocrinology Authors: MJ Davies, LJ Aronne, ID Caterson, AB Thomsen, PB Jacobsen, SP Marso, Tags: BRIEF REPORT Source Type: research
